StockData
NRX Pharmaceuticals, Inc. logo

NRX Pharmaceuticals, Inc. (NRXP) stock

NRXPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 0/30
$2.15−0.40 (-15.69%)

Close on Nov 20, 2026Market cap $93.09MP/E –Yield –

NRX Pharmaceuticals free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

NRX Pharmaceuticals's free cash flow for the twelve months ending Jun 30, 2025 was -$11.91M. For fiscal 2024 it was -$10.64M. The highest annual figure on record is -$2.27M in fiscal 2020.

Annual free cash flow

PeriodPeriod endValueChange
FY2024Dec 31, 2024-$10.64M–
FY2023Dec 31, 2023-$21.66M–
FY2022Dec 31, 2022-$39.77M–
FY2021Dec 31, 2021-$37.71M–
FY2020Dec 31, 2020-$2.27M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2025Jun 30, 2025-$4.03M–
Q1 FY2025Mar 31, 2025-$3.48M–
Q4 FY2024Dec 31, 2024-$2.10M–
Q3 FY2024Sep 30, 2024-$2.31M–
Q2 FY2024Jun 30, 2024-$2.56M–
Q1 FY2024Mar 31, 2024-$3.67M–
Q4 FY2023Dec 31, 2023-$3.19M–
Q3 FY2023Sep 30, 2023-$4.57M–
Q2 FY2023Jun 30, 2023-$7.81M–
Q1 FY2023Mar 31, 2023-$6.09M–
Q4 FY2022Dec 31, 2022-$8.32M–
Q3 FY2022Sep 30, 2022-$6.27M–
Q2 FY2022Jun 30, 2022-$14.79M–
Q1 FY2022Mar 31, 2022-$10.38M–
Q4 FY2021Dec 31, 2021-$11.28M–
Q3 FY2021Sep 30, 2021-$12.02M–

More NRX Pharmaceuticals figures

See a number that looks wrong?